{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T11:05:03Z","timestamp":1761217503515,"version":"3.37.3"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1124\/dmd.111.042614","type":"journal-article","created":{"date-parts":[[2011,10,27]],"date-time":"2011-10-27T00:46:00Z","timestamp":1319676360000},"page":"276-282","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Identification of UDP-Glucuronosyltransferases Responsible for the Glucuronidation of Darexaban, an Oral Factor Xa Inhibitor, in Human Liver and Intestine"],"prefix":"10.1016","volume":"40","author":[{"given":"Toshifumi","family":"Shiraga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanako","family":"Yajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenta","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Iwatsubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiji","family":"Miyashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Usui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.111.042614_bib1","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s11095-008-9823-9","article-title":"Relative importance of intestinal and hepatic glucuronidation\u2014impact on the prediction of drug clearance","volume":"26","author":"Cubitt","year":"2009","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.111.042614_bib2","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1021\/tx800323w","article-title":"Effect of intestinal glucuronidation in limiting hepatic exposure and bioactivation of raloxifene in humans and rats","volume":"21","author":"Dalvie","year":"2008","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.111.042614_bib3","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1538-7836.2010.03748.x","article-title":"Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2)","volume":"8","author":"Eriksson","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1124\/dmd.111.042614_bib4","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/S0090-9556(24)15100-8","article-title":"In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin","volume":"28","author":"Fisher","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.042614_bib5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1081\/DMR-120000653","article-title":"The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism","volume":"33","author":"Fisher","year":"2001","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.111.042614_bib6","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.taap.2004.01.008","article-title":"Regulation of UDP glucuronosyltransferases in the gastrointestinal tract","volume":"199","author":"Gregory","year":"2004","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1124\/dmd.111.042614_bib7","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1182\/blood.V116.21.3323.3323","article-title":"YM150, an oral direct inhibitor of factor Xa, demonstrated a predictable and dose-proportional pharmacokinetic\/pharmacodynamic profile after single and multiple dosing: results from three studies (Abstract)","volume":"116","author":"Groenendaal-van de Meent","year":"2010","journal-title":"Blood"},{"key":"10.1124\/dmd.111.042614_bib8","doi-asserted-by":"crossref","DOI":"10.1021\/jm200868m","article-title":"Discovery of N-[2-Hydroxy-6-(4-methoxybenzamido)phenyl]-4-(4-methyl-1,4-diazepan-1-yl)benzamide (Darexaban, YM150) as a potent and orally available factor Xa inhibitor","author":"Hirayama","year":"2011","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.111.042614_bib9","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0090-9556(24)15358-5","article-title":"In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model","volume":"28","author":"Houston","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.042614_bib10","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1124\/dmd.108.022731","article-title":"The configuration of 17-hydroxy group variably influences the glucuronidation of \u03b2-estradiol and epiestradiol by human UDP-glucuronosyltransferase","volume":"36","author":"It\u00e4aho","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.042614_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2011.10.009","article-title":"Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor","author":"Iwatsuki","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/dmd.111.042614_bib12","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1124\/dmd.109.027227","article-title":"Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers","volume":"37","author":"Izukawa","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.042614_bib13","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1182\/blood.V110.11.3153.3153","article-title":"Effects of direct factor Xa inhibitor, YM150, on clot formation and clot lysis in vitro compared with other anticoagulants (Abstract)","volume":"110","author":"Kaku","year":"2007","journal-title":"Blood"},{"key":"10.1124\/dmd.111.042614_bib14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.pharmthera.2004.10.013","article-title":"UDP-glucuronosyltransferases and clinical drug-drug interactions","volume":"106","author":"Kiang","year":"2005","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.111.042614_bib15","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1124\/dmd.108.023853","article-title":"Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes","volume":"37","author":"Kilford","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.042614_bib16","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/01.fpc.0000173483.13689.56","article-title":"Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily","volume":"15","author":"Mackenzie","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/dmd.111.042614_bib17","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3109\/03602539608994011","article-title":"The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine","volume":"28","author":"Milne","year":"1996","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.111.042614_bib18","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0163-7258(91)90065-T","article-title":"Drug glucuronidation in humans","volume":"51","author":"Miners","year":"1991","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.111.042614_bib19","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3109\/03602530903210716","article-title":"The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential","volume":"42","author":"Miners","year":"2010","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.111.042614_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.44.101802.121546","article-title":"Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches","volume":"44","author":"Miners","year":"2004","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/dmd.111.042614_bib21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1146\/annurev.pa.32.040192.000325","article-title":"Glucuronidation and its role in regulation of biological activity of drugs","volume":"32","author":"Mulder","year":"1992","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/dmd.111.042614_bib22","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1124\/dmd.108.021428","article-title":"Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines","volume":"36","author":"Nakamura","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.042614_bib23","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1124\/dmd.108.023598","article-title":"Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction","volume":"37","author":"Ohno","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.042614_bib24","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1081\/DMR-100101944","article-title":"Structural and functional studies of UDP-glucuronosyltransferases","volume":"31","author":"Radominska-Pandya","year":"1999","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.111.042614_bib25","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1124\/jpet.106.118216","article-title":"Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation","volume":"321","author":"Rowland","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.111.042614_bib26","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1124\/dmd.108.021105","article-title":"The \u201calbumin effect\u201d and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities","volume":"36","author":"Rowland","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.042614_bib27","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1182\/blood.V110.11.3155.3155","article-title":"Comparison of YM150, an oral, direct factor Xa inhibitor, with other antithrombotic agents in rodent venous and arterial thrombosis models (Abstract)","volume":"110","author":"Saitoh","year":"2007","journal-title":"Blood"},{"key":"10.1124\/dmd.111.042614_bib28","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1124\/jpet.301.1.382","article-title":"In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance","volume":"301","author":"Soars","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.111.042614_bib29","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1146\/annurev.pharmtox.40.1.581","article-title":"Human UDP-glucuronosyltransferases: metabolism, expression, and disease","volume":"40","author":"Tukey","year":"2000","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/dmd.111.042614_bib30","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1210\/endo.142.2.7958","article-title":"Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members","volume":"142","author":"Turgeon","year":"2001","journal-title":"Endocrinology"},{"key":"10.1124\/dmd.111.042614_bib31","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1038\/sj.bjp.0703235","article-title":"Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663","volume":"129","author":"van Heek","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1124\/dmd.111.042614_bib32","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1124\/dmd.30.12.1462","article-title":"Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10","volume":"30","author":"Watanabe","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.042614_bib33","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1124\/dmd.107.016097","article-title":"Glucuronidation of thyroxine in human liver, jejunum, and kidney microsomes","volume":"35","author":"Yamanaka","year":"2007","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562422612X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562422612X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.111.042614","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T20:05:35Z","timestamp":1739909135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009095562422612X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S009095562422612X"],"URL":"https:\/\/doi.org\/10.1124\/dmd.111.042614","relation":{},"ISSN":["0090-9556"],"issn-type":[{"type":"print","value":"0090-9556"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of UDP-Glucuronosyltransferases Responsible for the Glucuronidation of Darexaban, an Oral Factor Xa Inhibitor, in Human Liver and Intestine","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.111.042614","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2012 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}